Literature DB >> 15949003

Thalidomide in the management of epidermolysis bullosa pruriginosa.

S Ozanic Bulic1, H Fassihi, J E Mellerio, J A McGrath, D J Atherton.   

Abstract

Epidermolysis bullosa (EB) pruriginosa is a distinctive clinical subtype of dystrophic EB. We report a patient with dominant dystrophic EB pruriginosa, who had an excellent response to systemic thalidomide treatment. The mechanism of action of thalidomide in the management of pruriginous disorders is not yet completely understood. Most recent studies point towards an immunomodulatory action of thalidomide that may suppress excessive production of tumour necrosis factor-alpha and may downregulate certain cell surface adhesion molecules involved in leucocyte migration.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15949003     DOI： 10.1111/j.1365-2133.2005.06492.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

2.  Epidermolysis bullosa pruriginosa: A report of two cases.

Authors:  Varadraj Vasant Pai; Tukaram Sori; Kikkeri Narayanshetty Naveen; Sharatchandra Bhimrao Athanikar; Vijetha Rai; Dinesh Udupi Shastry
Journal:  Indian Dermatol Online J       Date:  2014-01

3.  Thalidomide in dermatology: revisited.

Authors:  Iffat Hassan; Konchok Dorjay; Parvaiz Anwar
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

4.  An incompletely penetrant novel mutation in COL7A1 causes epidermolysis bullosa pruriginosa and dominant dystrophic epidermolysis bullosa phenotypes in an extended kindred.

Authors:  Catherine S Yang; Yin Lu; Anita Farhi; Carol Nelson-Williams; Michael Kashgarian; Earl J Glusac; Richard P Lifton; Richard J Antaya; Keith A Choate
Journal:  Pediatr Dermatol       Date:  2012-04-20       Impact factor: 1.588

Review 5.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123

Review 6.  Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.

Authors:  May El Hachem; Giovanna Zambruno; Eva Bourdon-Lanoy; Annalisa Ciasulli; Christiane Buisson; Smail Hadj-Rabia; Andrea Diociaiuti; Carolina F Gouveia; Angela Hernández-Martín; Raul de Lucas Laguna; Mateja Dolenc-Voljč; Gianluca Tadini; Guglielmo Salvatori; Cristiana De Ranieri; Stephanie Leclerc-Mercier; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2014-05-20       Impact factor: 4.123

7.  Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer.

Authors:  Long Xia Chen; Xiao Ling Ni; Heng Zhang; Min Wu; Jing Liu; Shan Xu; Ling Lin Yang; Shao Zhi Fu; Jingbo Wu
Journal:  Int J Nanomedicine       Date:  2018-04-23

8.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.